Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: "in explicit technical detail"

The criteria we have outlined for M&A will target revenue-producing companies at, or near, operating profitability in niche, growth markets. I expect that we will use a combination of cash, equity, and less likely debt to accomplish these objectives.

from shareholder letter

 

what you think 30 40 mio dollar lol

take 300-400mio dollar with nasdaq or amex maybe 800mio with revenues stream

so with what money till end of year

ptsc will go to 2$ and more we have only to wait thats all

Share
New Message
Please login to post a reply